Related references
Note: Only part of the references are listed.Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon et al.
DIABETES CARE (2017)
Effect of Linagliptin on Arterial 18F-Fluorodeoxyglucose Positron Emission Tomography Uptake
Stefanie A. de Boer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference
Colin Baigent et al.
KIDNEY INTERNATIONAL (2017)
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Adeera Levin et al.
LANCET (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial
Per-Henrik Groop et al.
DIABETES OBESITY & METABOLISM (2017)
Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus A Population-Based Cohort Study
Young-Gun Kim et al.
CIRCULATION-HEART FAILURE (2017)
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Nikolaus Marx et al.
DIABETES CARE (2017)
Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE)
Stefanie A. de Boer et al.
DIABETES OBESITY & METABOLISM (2017)
EMPA-REG OUTCOME: The Nephrologist's Point of View
Christoph Wanner
AMERICAN JOURNAL OF CARDIOLOGY (2017)
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes
Thomas Jax et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal et al.
DIABETES OBESITY & METABOLISM (2017)
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Merlin C. Thomas et al.
NATURE REVIEWS NEPHROLOGY (2016)
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study
Huang-Tz Ou et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Robert J. Smith et al.
DIABETES CARE (2016)
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan H. Cornel et al.
DIABETES CARE (2016)
An update on DPP-4 inhibitors in the management of type 2 diabetes
Avivit Cahn et al.
EXPERT OPINION ON EMERGING DRUGS (2016)
Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study
Dimitrios Baltzis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy
Oleg Tsuprykov et al.
KIDNEY INTERNATIONAL (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire et al.
JAMA CARDIOLOGY (2016)
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Sen Shi et al.
FIBROGENESIS & TISSUE REPAIR (2016)
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
Mark E. Cooper et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Julio Rosenstock et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Nikolaus Marx et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition
Sen Shi et al.
KIDNEY INTERNATIONAL (2015)
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faiez Zannad et al.
LANCET (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFβ through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin
Muralikrishna Gangadharan Komala et al.
PLOS ONE (2015)
GFR Decline as an End Point in Trials of CKD: A Viewpoint From the FDA
Aliza Thompson et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
GFR Decline as an End Point for Clinical Trials in CKD: A View From Europe
Peter G. M. Mol et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Per-Henrik Groop et al.
DIABETES CARE (2013)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Ron T. Gansevoort et al.
LANCET (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin
U. Graefe-Mody et al.
DIABETES OBESITY & METABOLISM (2011)
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
Andrew S. Levey et al.
KIDNEY INTERNATIONAL (2011)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
